Abiopharma

🔍 Sarner Michael Scott (Director)

Company: CAPITAL SOUTHWEST CORP (CSWC)

Report Date: 2026-06-09

Detailed Transactions and Holdings:

• Sold 13,765 shares of Common Stock at $23.28 per share (Direct)
  Date: 2026-06-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 459,389.34 | transaction_form_type: 4 | Footnotes: F1
• Acquired 140,000 shares of Common Stock (Direct)
  Date: 2026-06-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 599,389.34 | transaction_form_type: 4 | Footnotes: F2
• Sold 11,705 shares of Common Stock at $23.54 per share (Direct)
  Date: 2026-06-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 587,684.34 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Shares withheld for payment of tax liability upon vesting of restricted shares granted under the Capital Southwest Corporation 2021 Employee Restricted Stock Award Plan. This withholding transaction was approved by the Compensation Committee of Capital Southwest's Board of Directors in accordance with Rule 16b-3(d)(1) of the Securities Exchange Act of 1934 (the "Act"), and as such, the sale is exempt from section 16(b) of the Act pursuant to Rule 16b-3(e) promulgated thereunder.
• F2: Shares issued under the Capital Southwest Corporation 2021 Employee Restricted Stock Award Plan.